Evidence map›Paper›PMID 25632215›Full record

ArticleWorld journal of gastroenterology2015

Partial embolization as re-treatment of hypersplenism after unsuccessful splenic artery ligation.

Zheng-Ju Xu, Lian-Qiu Zheng, Xing-Nan Pan

Open access · hybridAbstract readCase Reports
In one paragraph

Article in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Zheng-Ju XuZheng-Ju Xu, Lian-Qiu Zheng, Xing-Nan Pan, Clinical Liver Center, 180 Hospital of the People's Liberation Army, Quanzhou 362000, Fujian Province, China.
Lian-Qiu ZhengZheng-Ju Xu, Lian-Qiu Zheng, Xing-Nan Pan, Clinical Liver Center, 180 Hospital of the People's Liberation Army, Quanzhou 362000, Fujian Province, China.
Xing-Nan PanZheng-Ju Xu, Lian-Qiu Zheng, Xing-Nan Pan, Clinical Liver Center, 180 Hospital of the People's Liberation Army, Quanzhou 362000, Fujian Province, China.
The 180th Hospital of PLA · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ligation of splenic artery (LSA) is used for the treatment of liver cirrhosis with hypersplenism. However, hypersplenism is not significantly improved following LSA treatment in some cases, and there are few reports of retreatment of hypersplenism after LSA. We report the case of a 47-year-old man with liver cirrhosis and hypersplenism who underwent LSA treatment, but did not significantly improve. Laboratory tests revealed severe leukocytopenia and thrombocytopenia. Celiac computed tomography arteriogram and digital subtraction angiography revealed two compensatory arteries connected to the hilar splenic artery from the left gastro-epiploic artery and from the dorsal pancreatic artery. Partial splenic embolization (PSE) was performed through the compensatory arteries. As a result, the patient achieved partial splenic ischemic infarction, and white blood cell and platelet counts rose and remained in the normal range. PSE is an effective therapeutic modality for the retreatment of hypersplenism when other modalities have failed.

Indexed as

Angiography, Digital SubtractionCollateral CirculationEmbolization, TherapeuticHumansHypersplenismLigationLiver CirrhosisMaleMiddle AgedRegional Blood FlowSplenic ArteryTomography, X-Ray ComputedTreatment FailureHypersplenismLeukocytopeniaLiver cirrhosisPartial splenic embolizationSplenic artery ligationThrombocytopenia

Identifiers

PMID25632215
PMCPMC4306186
OpenAlexW2060736525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.